1. Home
  2. FEAM vs IMA Comparison

FEAM vs IMA Comparison

Compare FEAM & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

HOLD

Current Price

$2.30

Market Cap

56.9M

Sector

Industrials

ML Signal

HOLD

IMA

ImageneBio Inc.

N/A

Current Price

$4.08

Market Cap

66.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FEAM
IMA
Founded
2016
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
66.3M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
FEAM
IMA
Price
$2.30
$4.08
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$5.88
★ $18.00
AVG Volume (30 Days)
★ 766.5K
10.7K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.80
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $800,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$81.81
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.90
$3.90
52 Week High
$6.03
$9.10

Technical Indicators

Market Signals
Indicator
FEAM
IMA
Relative Strength Index (RSI) 41.42 30.51
Support Level $1.38 $3.92
Resistance Level $2.49 $6.13
Average True Range (ATR) 0.45 0.19
MACD -0.18 0.00
Stochastic Oscillator 3.15 21.95

Price Performance

Historical Comparison
FEAM
IMA

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: